Search This Blog

Wednesday, April 22, 2026

Bessent says $14 billion Iran sanctions relief claim is ‘a myth’

 

US Treasury Secretary Scott Bessent said Wednesday that claims Iran could gain $14 billion from temporary US sanctions relief are “a myth,” defending Washington’s decision to allow some Iranian oil already at sea to reach markets.

Bessent said the Treasury was able to unlock more than 250 million barrels “on the water” through sanctions relief and argued oil prices would have been higher without the move.

https://www.iranintl.com/en/liveblog/202604194357

Iran lawmaker says nuclear issue should not have been raised in Pakistan talks

 

Iranian lawmaker Mahmoud Nabavian said on Wednesday that Iran made a strategic mistake by allowing the nuclear issue to be discussed in talks in Pakistan, saying it emboldened the United States to make further demands.

“In the Pakistan negotiations, we made a strategic mistake. We should not have put the nuclear issue up for negotiation,” Nabavian, a member of parliament’s National Security and Foreign Policy Committee, told state-affiliated SNN.

“By doing so, the enemy became bolder,” he added.

Nabavian said the United States demanded that Iran’s 60% enriched material be removed and blocked for 20 years, demands he said Tehran did not accept.

https://www.iranintl.com/en/liveblog/202604194357

Greece confirms its cargo ship was attacked in Hormuz

 Greek Minister of Foreign Affairs Giorgos Gerapetritis (pictured) told CNN on Wednesday that a Greek-owned cargo ship was attacked near the Strait of Hormuz, adding that it is "unclear" if it was seized by the Iranian forces.

"It was a Liberian-flagged and Greek-owned ship, it was trying to get out of the Strait of Hormuz," Gerapetritis said. "We have sent an overall notice to all Greek-owned ships to be very mindful, to exercise maximum self-restraint and to avoid crossing the strait," he added.

The United Kingdom Maritime Trade Operations (UKMTO) previously announced that three ships were attacked in the Strait of Hormuz, with one of them being the Greek-flagged Epaminondas, which sustained "heavy damage" to the bridge. Meanwhile, Iran's Islamic Revolutionary Guard Corps (IRGC) Navy forces reported enforcing "maritime law" on a container ship after the vessel allegedly "ignored repeated warning."

https://breakingthenews.net/Article/Greece-confirms-its-cargo-ship-was-attacked-in-Hormuz/66125212

FDA Expands Teplizumab-Mzwv Approval to Delay Stage 3 Type 1 Diabetes in Children as Young as 1 Year

 The FDA has approved a supplemental biologic license application (sBLA) for teplizumab-mzwv (Tzield, Sanofi), expanding its approved age range from 8 years and older down to as young as 1 year of age to delay the onset of stage 3 type 1 diabetes (T1D) in patients diagnosed with stage 2 T1D. The approval was granted under priority review and makes teplizumab the first disease-modifying therapy available for children in this younger age group.






https://www.pharmacytimes.com/view/fda-expands-teplizumab-mzwv-approval-to-delay-stage-3-type-1-diabetes-in-children-as-young-as-1-year

Anthropic’s Mythos Model Is Being Accessed by Unauthorized Users

 


A small group of unauthorized users have accessed Anthropic PBC’s new Mythos AI model, a technology that the company says is so powerful it can enable dangerous cyberattacks, according to a person familiar with the matter and documentation viewed by Bloomberg News.

A handful of users in a private online forum gained access to Mythos on the same day that Anthropic first announced a plan to release the model to a limited number of companies for testing purposes, said the person, who asked not to be named for fear of reprisal. The group has been using Mythos regularly since then, though not for cybersecurity purposes, said the person, who corroborated the account with screenshots and a live demonstration of the model.

https://www.bloomberg.com/news/articles/2026-04-21/anthropic-s-mythos-model-is-being-accessed-by-unauthorized-users

Amneal details $750M Kashiv BioSciences acquisition

 

Amneal beats Q1 2026 estimates with EPS $0.27 (+29% YoY), revenue $722.5M (+4% YoY), details $750M Kashiv BioSciences acquisition

  • Amneal to acquire Kashiv BioSciences for $375M cash, $375M equity plus up to $350M milestone and royalty payments
  • Company filed SEC report today disclosing Q1 2026 results and details of the $750M Kashiv acquisition

Boston Scientific beats, but issues Q2 EPS guidance $0.82–$0.84, reaffirms 2026 EPS outlook $3.34–$3.41

 

Boston Scientific beats Q1 2026 estimates with non-GAAP EPS $0.80, revenue $5.203B, issues Q2 EPS guidance $0.82–$0.84, reaffirms 2026 EPS outlook $3.34–$3.41

  • GAAP net income reached $1.34B in Q1 2026, approximately doubling compared with the prior-year period.
  • Company expects 2026 sales growth of 7.0–8.5% and EPS of $3.34–$3.41.